KR20210139279A - 퀴나졸리논 화합물 - Google Patents

퀴나졸리논 화합물 Download PDF

Info

Publication number
KR20210139279A
KR20210139279A KR1020217030721A KR20217030721A KR20210139279A KR 20210139279 A KR20210139279 A KR 20210139279A KR 1020217030721 A KR1020217030721 A KR 1020217030721A KR 20217030721 A KR20217030721 A KR 20217030721A KR 20210139279 A KR20210139279 A KR 20210139279A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
alkyl
alkoxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217030721A
Other languages
English (en)
Korean (ko)
Inventor
빙웨이 루
Original Assignee
셀리퓨트, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀리퓨트, 인코포레이티드 filed Critical 셀리퓨트, 인코포레이티드
Publication of KR20210139279A publication Critical patent/KR20210139279A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020217030721A 2019-02-27 2020-02-26 퀴나졸리논 화합물 Pending KR20210139279A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811471P 2019-02-27 2019-02-27
US62/811,471 2019-02-27
PCT/US2020/019942 WO2020176652A1 (en) 2019-02-27 2020-02-26 Quinazolinone compounds

Publications (1)

Publication Number Publication Date
KR20210139279A true KR20210139279A (ko) 2021-11-22

Family

ID=72238692

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030721A Pending KR20210139279A (ko) 2019-02-27 2020-02-26 퀴나졸리논 화합물

Country Status (9)

Country Link
US (1) US12454514B2 (https=)
EP (1) EP3930837A4 (https=)
JP (1) JP7597722B2 (https=)
KR (1) KR20210139279A (https=)
CN (1) CN113747943A (https=)
AU (1) AU2020228374A1 (https=)
CA (1) CA3131294A1 (https=)
IL (1) IL285805A (https=)
WO (1) WO2020176652A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07107056B2 (ja) * 1987-01-30 1995-11-15 日清製粉株式会社 ４（３ｈ）−キナゾリノン誘導体、その製造方法およびそれを有効成分とする抗潰瘍剤
US7381730B2 (en) * 2002-03-15 2008-06-03 Bristol-Myers Squibb Company 3-arylquinazoline derivatives as selective estrogen receptor beta modulators
US20050038051A1 (en) * 2003-06-09 2005-02-17 Jodi Nunnari Novel molecules for regulating cell death
US9492450B2 (en) * 2011-04-19 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Inhibition of dynamin related protein 1 to promote cell death
WO2013025508A1 (en) * 2011-08-12 2013-02-21 Southern Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
JP2013142070A (ja) 2012-01-11 2013-07-22 Nihon Univ ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服
CN111372921B (zh) * 2017-09-13 2023-12-01 赛勒佩特公司 小分子化合物
US11559527B2 (en) 2017-12-20 2023-01-24 Lunella Biotech, Inc. Targeting mitochondrial fission through mDIVI-1 derivatives
US20190307749A1 (en) * 2018-04-10 2019-10-10 Texas Tech University System Mitochondria-Division Inhibitor 1 Protects Against Amyloid-B Induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer's Disease

Also Published As

Publication number Publication date
US20220162172A1 (en) 2022-05-26
US12454514B2 (en) 2025-10-28
AU2020228374A1 (en) 2021-09-23
WO2020176652A1 (en) 2020-09-03
EP3930837A4 (en) 2022-10-05
IL285805A (en) 2021-10-31
JP2022523383A (ja) 2022-04-22
CN113747943A (zh) 2021-12-03
JP7597722B2 (ja) 2024-12-10
CA3131294A1 (en) 2020-09-03
EP3930837A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TWI891621B (zh) 一種噠嗪類衍生物抑制劑、其製備方法和應用
US6395750B1 (en) Drugs for the treatment of malignant tumors
TWI662026B (zh) 吡啶酮類衍生物、其製備方法及其在醫藥上的應用
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
WO2022105908A1 (zh) Egfr抑制剂及其制备方法与在药学上的应用
JP2008505907A (ja) 癌治療を目的として肝細胞増殖因子およびｃ−ｍｅｔ活性を調整するキナゾリンモジュレーター
KR102765158B1 (ko) 티에노피리미딘 유도체 및 이의 용도
UA128528C2 (uk) Похідна піридопіримідину, спосіб її отримання та її медичне застосування
JP6670913B2 (ja) 白血病を予防および治療するためのマレイミド誘導体の使用
JP2015533778A (ja) がんの治療のための新規フェニル−ピリジン／ピラジンアミド
KR20170108150A (ko) 항암 화합물
CN111349093B (zh) 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
KR20210139279A (ko) 퀴나졸리논 화합물
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
CN111848572B (zh) 酰胺类化合物及其制备方法和用途
CN111620874A (zh) 取代5,6-双杂环氨基化合物作为wnt信号通路抑制剂及其治疗应用
KR20200053560A (ko) 신규한 소분자 화합물
CN113717148B (zh) 一种杂芳酰胺类化合物、其制备方法及应用
CN110996930B (zh) 新型亚苄基丙酮衍生物及其用途
EP2625168A1 (en) Phenyl diamides and a pharmaceutical preparation comprising phenyl diamides
WO2022237825A1 (zh) 具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
WO2016127949A1 (zh) 作为t790变异抑制剂的嘧啶衍生物
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
KR20210151849A (ko) 퀴놀린 유도체 및 암의 치료를 위한 그의 용도
KR100525706B1 (ko) 항암활성을 갖는 인돌퀴논 유도체 및 이의 제조방법

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701